Početna › Prekomjerna tjelesna masa › North Carolina
Kliničke studije za Prekomjerna tjelesna masa u državi North Carolina
40 studija za Prekomjerna tjelesna masa traži sudionike na lokacijama u državi North Carolina.
Gradovi u državi North Carolina
- Havelock17 studija
- Charlotte15 studija
- Greensboro12 studija
- Wilmington11 studija
- Durham7 studija
- Winston-Salem6 studija
- Statesville5 studija
- Raleigh5 studija
- Cary4 studija
- Fayetteville4 studija
- New Bern4 studija
- Greenville3 studija
Službeni tekst studije (engleski)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Medication Management /ID# 281965, Greensboro
- Monroe Biomedical Research /ID# 282009, Monroe
- Centricity Research - Morehead city /ID# 283264, Morehead City
- i još 2
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
- University of North Carolina at Chapel Hill, Chapel Hill
U tijeku regrutacija
Od 18 do 75 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT06724406Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- TMA Headlands, Wilmington
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Medication Mgmnt, LLC_Grnsboro, Greensboro
- Accellacare of Raleigh, Raleigh
- Accellacare-Salisbury PMG Res, Salisbury
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- PharmQuest Life Sciences LLC, Greensboro
- Piedmont Healthcare/Research, Statesville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- West Clinical Research, Morehead City
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Medication Management, LLC, Greensboro
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Statesville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UNC Children's Hospital, Chapel Hill
- Duke Children's Primary Care, Durham
- Lucas Research, Inc, Morehead City
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Coastal Research Institute - Fayetteville, Fayetteville
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- PharmQuest Life Sciences, LLC, Greensboro
- West Clinical Research, Morehead City
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- University of North Carolina Medical Center, Chapel Hill
- Medication Management, Greensboro
- Carteret Medical Group, Morehead City
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- i još 7
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Monroe
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- i još 1
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Charlotte
- AURORA-1 Clinical Site, Greenville
- AURORA-1 Clinical Site, Morehead City
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Charlotte
- AURORA-2 Clinical Site, Durham
- AURORA-2 Clinical Site, Greenville
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centricity Research Morehead City Multispeciality, Morehead City
- Wake Forest University Health Sciences, Winston-Salem
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Lucas Research, Inc., Morehead City
- Shelby Clinical Research, Shelby
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Charlotte
- ACCOMPLISH-2 Research Site, Durham
- ACCOMPLISH-2 Research Site, Fayetteville
- i još 2
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- i još 1
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Revival Research Institute, LLC, Cary
- Onsite Clinical Solutions - Huntersville, Huntersville
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07745504Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Greensboro
- Kailera Clinical Site, Monroe
- Kailera Clinical Site, Morehead City
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Accellacare of Hickory, Hickory
- Carolina Research Center Inc, Shelby
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- West Clinical Research, Morehead City
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684144Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Centricity Research Morehead City Specialty, Morehead City
- Accellacare of Raleigh, Raleigh
- Accellacare Research of Wilmington, Wilmington
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Statesville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Piedmont Healthcare/Research, Statesville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Charlotte
- ACCOMPLISH-1 Research Site, Durham
- ACCOMPLISH-1 Research Site, Fayetteville
- i još 3
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Monroe Biomedical Research, LLC, Monroe
- Accellacare, Wilmington
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. lip 2026. · NCT07607587A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
- Monroe Biomedical Research, Monroe
U tijeku regrutacijaFaza 2
Od 18 do 60 godina · Oba spola · Ažurirano 22. lip 2026. · NCT07570758Pregnancy Exercise Mode Effect on Childhood Obesity
- East Carolina University, Greenville
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 45 godina · Žene · Ažurirano 4. lip 2026. · NCT04805502NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- Wake Forest University Health Sciences, Winston-Salem
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 39 godina · Žene · Ažurirano 27. velj 2026. · NCT05674799A Mobile Intervention to Reduce Pain and Improve Health-III
- Wake Forest University, Winston-Salem
U tijeku regrutacijaFaza 2
Od 65 godina i više · Oba spola · Ažurirano 20. velj 2026. · NCT06623669MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
- True You Weight Loss, Cary
- True You Weight Loss, Cary
U tijeku regrutacija
Od 21 do 65 godina · Oba spola · Ažurirano 21. ožu 2025. · NCT06734312REvision of VSG with Ablation of the Mucosa Procedure
- True You Weight Loss, Cary
U tijeku regrutacija
Od 22 do 60 godina · Oba spola · Ažurirano 5. stu 2024. · NCT06671119Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.